C5aR1 antagonist therapy(Vanqua Bio)

N/A

Report date: 2024/03/27 17:50:09

Base Information

Drug NameC5aR1 antagonist therapy(Vanqua Bio)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionC5a anaphylatoxin chemotactic receptor 1 antagonists

TargetsC5a anaphylatoxin chemotactic receptor 1

Therapy Area/IndicationsInflammationAlzheimer DiseaseMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVanqua Bio Inc

China Registration ClassN/A

Active CompaniesVanqua Bio Inc

Inactive CompaniesN/A

Active IndicationsInflammationAlzheimer DiseaseMultiple Sclerosis

Inactive IndicationsN/A

ATC CodeN/A